Unable to display view head.php file not found.
There have been several meta-analyses of the value of the NOACs versus warfarin. Figure 13 (right) illustrates an analysis published by Dentali.[20] Looking at the NOACs together, we can see that there is a significant reduction in all-cause mortality and cardiovascular mortality, both about 11%; a significant reduction in stroke or systemic embolism, about 23%; and a significant reduction in intracranial hemorrhage, approximately 54%. There are also trends towards a reduction of ischemic stroke and major bleeding. Camm J. Am J Med 2013; published on-line at http://education.amjmed.com/00000.
[19] Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118:321-333.
[20] Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation. 2012;126:2381-2391.